Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for	r form 14	49A/PTO			Complete if Known	
				Application Number		D T
INFORMATION DISCLOSURE				Filing Date	herewith	386
S	STATEMENT BY APPLICANT			First Named Inventor	Chinery	7.0
				Group Art Unit		00
(use as many sheets as necessary)			y sheets as necessary)	Examiner Name		80
Sheet	1	of	3	Attorney Docket Number	ATH 108 CON1	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines, Where	
	1 1	Number	Kind Code (if known)	of Cited Document	of Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	
	AA	5,035,878		Borsch	07-30-1991		
	AB	5,155,250		Parker	10-13-1992		
	AC	5,262,439		Parthasarathy	11-16-1993		
	AD	5,294,430		Borsch	03-15-1994		
	AE	5,608,095		Parker et al.	03-04-1997		
				10-10-10-10-10-10-10-10-10-10-10-10-10-1			

				FOREIG	N PATENT DOCUMENTS			
Examiner	Cite	I. I EKING GOGE I	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or			
Initials*	No.	Office	Number	(if known)	of Cited Document	MM-DD-YYYY	Relevant Figures Appear	T
	AF		WO 95/15760		Merrell Dow Pharm.	06-15-1995		
	AG		WO 95/26719		Arcturus Pharm.	10-12-1995		
	AH		WO 93/20691		Tykocinski	10-28-1993	p. 5-8, claim 8	
	Al		WO 95/09365		Univ of NY	04-06-1995		
						-		
							•	
Examine						Date		
Signature	€					Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hsould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known	5	
				Application Number			-
INFORMATION DISCLOSURE				Filing Date	2/7/01	790 190 	D/6
S	TAT	EMEN	IT BY APPLICANT	First Named Inventor	Chinery	- S	/0/
				Group Art Unit		60	02
	(use	e as man	y sheets as necessary)	Examiner Name			
Sheet	2	of	3	Attorney Docket Number	ATH 108 CON1		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	BA	COFFEY, et al., Cancer Res . 47, 4590 (1987)	
	BB	CROOK, et al. Oncogene 6, 873 (1991)	
	ВС	SCHEFFNER, et al. Proc. Natl. Acad. Sci. U.S.A. 88, 5523 (1991)	
	BD	RIPOLL, et al., Vitimin E Enhances the Chemotherapeutic Effects of Adriamycin, <i>Biological Abstracts</i> , 82, 82084938	
	BE	YAUNAGA et al., Vitimin E and Cancer Therapy-Experimental Study in Mice, Database National Cancer Institute, 1982.	
	BF	SZCZEPANSKA et al., Inhibition of Leukocyte Migration by Cancer Chemotherapeutic Agents and its Prevention by Free Radical Scavengers and Thiols, Biological Abstracts Vol. 85, 85106445	
	BG	PRASAD et al., Vitamin E Increases the Growth Inhibitoryuy and Differenciating Effects of Tumor Therapeutic Agents on Neuro Blastoma and Glioma Cells in Culture, Biological Abstracts, vol. 70, 70052454	
	вн	DRAGO, et al., Chemptherapy and Vitamin E in Treatment of NB Rat Prostrate Tumors, Biological Abstracts Vol. 88, 88006807	
	ВІ	CLOOS JACQUELINE JAN, Influence of the antioxidant N-acetylcysteine annd its metabolites on Damge induced by Bleomycin in PM2 Bacteriophage, <i>Biological Abstracts</i> , Vol. 96, 98730849.	
	BJ	RIORDAN et al., Case study: High Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney, <i>J. Orthomolecular Med.</i> , 5:1, 1990, 5-7.	
	BK	CAMPBELL et al., Retticulum Cell Sarcoma: Two Complete "Spontaneous" Regressions, in Response to High-Dose Ascorbic Acid Therapy, <i>Oncology, 48</i> : 6 (1991), 495-497.	
	BL	BONGERS, Antioxidant-Related Parameters in Patients Treated for Cancer Chemoprevention with Nacetylcysteine, <i>Biological Abstracts</i> , vol. 95, 98363146.	
	ВМ	OFFERMAN, etal. AntooxidantSensitive Regulation of Inflammatory_Response Genes in Kaposi's Sarcoma Cells, <i>J. of AIDS and Hum. Retro.</i> , (1996) 13:1-11.	
	BN	TYAGI S C, Reduction-Oxidation state Regulation of Extracellular Matrix Metalloproteinases and Tissue Inhibitors in Cardiac Normal and Transformed Fibroblast Cells, <i>Biological Abstracts</i> , vol. 96, 98730849.	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	Substitute for form 1449A/PTO				Complet if Known	
				Application Number		
"	NFOF	RMATIO	N DISCLOSURE	Filing Date	2/7/01	
S	TAT	EMENT	BY APPLICANT	First Named Inventor	Chinery	
				Group Art Unit		
(use as many sheets as necessary)				Examiner Name		
Sheet	3	of	3	Attorney Docket Number	ATH 108 CON1	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	CA	ROESL, Differential Regulation of the JE Gene Encoding the Monocyte Chemoattractant Protein (MCP-1) in Cerviacl Carcinoma Cells and Derived Hybrids, <i>Biological Abstracts</i> , Vol. 94, 97193049	
	СВ	KOWENS-LEUTZ, et al., Novel Mechanism of C/EPBbeta (NF-M) Transcriptional Control: Activation Through Derepression, <i>Genes and Development</i> , 8:1994, 2781-2791.	
	СС	FAVRE et al., The catalytic Subunit of protein Phophatase 2A is Carboxyl-methylated in vivo, <i>J. of Biol. Chem.</i> , 269:23, (1994), 16311-16317.	
	CD	TRAUTWIEN et al., Protein Kinease A and C Site-Specific Phosphorylations of LAP (nf-IL6) Modulate its Binding Affinity to DNA Recognition Elelments, <i>J. of Clin. Investig.</i> , 93:6, (1994) 2554-2561	
	CE	WPI Derwent Publications Ltd., 97-373441 1995.	
		WPI Derwent Publications Ltd., 96-157002 1996.	
	EA	CHINERY, R. et al. Antioxidant-induced Nuclear Translocation of CCAAT/Enhancer-binding Protein beta Journal of Biological Chemistry 272: 30356-30361 (1997)	
	EB	CHINERY, R. et al. Antioxidant-induced Nuclear Translocation of CCAAT/Enhancer-binding Protein beta Journal of Biological Chemistry 272: 30356-30361 (1997)	
	EC	Berkowitz et al. Tet. Lett. Vol. 35, No. 35, pages 6445-6448 (July 1994)	
	_	Mahoney et al., J. Biol. Chem. Vol. 267, No. 27 pages 19396-19403 (July 1994)	
	EF	Abstract to Hedricks-Taylor et al. Genomics, Vol. 14(1) pages 12-17 (Jan. 1992)	

Examiner	Date	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.